3 New Strong Buy Ratings from Top-Rated Analysts: 09/08/2026
What are Wall Street’s brightest and best minds watching this week? These stocks…
- Veracyte (VCYT): Top-rated analysts see BIG upside potential
- Protagonist Therapeutics (PTGX): 10 analysts are bullish after a fresh FDA approval
- Semtech (SMTC): Experts believe there’s over 100% upside ahead (!!)
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
1. Veracyte (NASDAQ: VCYT)
Veracyte uses genomic testing to help doctors diagnose and guide treatment for cancers like thyroid and prostate cancer. Demand for its precision medicine tests is growing quickly, giving the company an expanding role in the shift toward more personalized cancer care.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $42.53 — get current quote
Max 1-year forecast: $69.00
Why we're watching:
- VCYT has strong, bullish coverage among the analysts we track, with 5 Strong Buy, 1 Buy, and 1 Hold recommendations. See all recommendations here
- For example, Piper Sandler researcher David Westenberg (a top 1% rated analyst) recently maintained his Strong Buy rating with a price target suggesting the stock could see nearly 30% upside in the coming year.
- Even more bullish, Guggenheim researcher Subbu Nambi (a top 2% rated analyst) maintained his Strong Buy with a price target suggesting the stock could see greater than 50% upside in the coming year.
- Industry ranking context: VCYT is currently the #11 highest-rated stock in the Biotech industry … but note that this industry is notoriously volatile and earns an F rating.
- Zen Ratings highlights: VCYT earns an overall A rating, equal to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all 4,600+ stocks tracked based on a rigorous 115-factor fundamental review.
- Component Grades: VCYT delivers a standout B for Sentiment alongside strong Bs for Financials, Safety, and Value, reflecting robust analyst confidence and solid fundamental health despite operating in a challenging biotech sector. See all 7 Component Grades here
2. Protagonist Therapeutics (NASDAQ: PTGX)
Protagonist Therapeutics develops peptide-based medicines for serious diseases. The recent FDA approval of MIMRYLO gives the company a major new commercial opportunity, while its strong cash position provides plenty of support for future drug development.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $145.72 — get current quote
Max 1-year forecast: $186.00
Why we're watching:
- PTGX has solid, bullish coverage among the analysts we track, with 6 Strong Buy and 4 Buy recommendations. See all recommendations here
- For example, Barclays researcher Etzer Darout (a top 1% rated analyst) recently maintained his Strong Buy recommendation with a price target suggesting the stock could see around 25% upside in the coming year.
- Likewise, Citigroup researcher Geoff Meacham (a top 5% rated analyst) maintains a Strong Buy with a similar price target.
- Seven additional top-tier analysts recommend the stock as a Buy or better, all maintaining bullish outlooks on the company's therapeutic opportunities.
- Industry ranking context: PTGX is currently the #10 highest-rated stock in the Biotech industry, which has an Industry Rating of F.
- Zen Ratings highlights: PTGX earns an overall A rating, equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: PTGX excels with an A for both Financials and Growth, supported by a strong B for Momentum, reflecting the company's impressive profit margin and accelerating commercial traction following recent regulatory wins. See all 7 Component Grades here
3. Semtech Corp (NASDAQ: SMTC)
Semtech makes specialized chips and connectivity technology used in data centers and IoT devices. The company is gaining momentum as AI infrastructure and connected-device demand grow, with strong recent results showing its strategy is paying off.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $147.89 — get current quote
Max 1-year forecast: $300.00
Why we're watching:
- SMTC has solid, bullish coverage among the analysts we track, with 8 Strong Buy, 6 Buy, and 1 Hold recommendations. See all recommendations here
- For example, Baird researcher Craig Ellis (a top 1% rated analyst) recently maintained his Buy recommendation with a price target suggesting the stock could see greater than 100% upside in the coming year.
- More modest, but still pretty darned good, UBS researcher Timothy Arcuri (a top 1% rated analyst) maintained his Strong Buy with a price target suggesting the stock could see greater than 50% upside.
- Six additional top 1% analysts within our system all maintain bullish outlooks on the semiconductor sector's growth trajectory.
- Industry ranking context: SMTC is currently the #3 highest-rated stock in the Semiconductor industry, which has an Industry Rating of A.
- Zen Ratings highlights: SMTC earns an overall A rating, which amounts to a Strong Buy recommendation. This tier represents the elite top 5% of stocks tracked based on a rigorous 115-factor fundamental analysis.
- Component Grades: SMTC excels with an A for Growth alongside strong Bs for Financials, Momentum, Safety, and Sentiment, a combination that reflects the company's accelerating revenue trajectory and expanding market opportunities in data center infrastructure. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.